Skip to main content
. 2014 Jul 18;7:459. doi: 10.1186/1756-0500-7-459

Table 4.

MGH-SFI item scores by ADT group and gender (safety sample)

MGH-SFI item
Bupropion plus aripiprazole, mean (SE)
SSRI/SNRI plus aripiprazole, mean (SE)
  Baseline Change from baseline at Week 52 (OC) Change from baseline at Week 52 (LOCF) Baseline Change from baseline at Week 52 (OC) Change from baseline at Week 52 (LOCF)
Males, n
13
5
13
69
21
69
  Interest in sex
2.8 (0.3)
-0.2 (0.9)
0.0 (0.4)
3.8 (0.2)
-0.5 (0.4)
-0.3 (0.2)
  Ability to get sexually aroused
3.1 (0.3)
0.0 (0.8)
-0.1 (0.3)
3.9 (0.2)
-0.8 (0.3)
-0.3 (0.2)
  Ability to achieve orgasm
3.2 (0.4)
-0.4 (1.1)
-0.2 (0.4)
4.0 (0.2)
-0.7 (0.4)
-0.4 (0.2)
  Ability to get erection
3.7 (0.4)
-1.2 (0.4)
-0.6 (0.2)
3.7 (0.2)
-0.3 (0.4)
-0.2 (0.2)
  Overall sexual satisfaction
3.9 (0.4)
-1.4 (0.2)
-0.7 (0.3)
4.1 (0.2)
-0.6 (0.3)
-0.4 (0.2)
Females, n
24
14
24
147
48
147
  Interest in sex
3.9 (0.3)
-0.5 (0.3)
-0.5 (0.3)
4.6 (0.1)
-0.9 (0.2)
-0.9 (0.1)
  Ability to get sexually aroused
4.0 (0.3)
-0.4 (0.5)
-0.5 (0.3)
4.6 (0.1)
-0.9 (0.2)
-0.7 (0.1)
  Ability to achieve orgasm
3.9 (0.4)
-0.3 (0.5)
-0.3 (0.3)
4.6 (0.1)
-0.8 (0.2)
-0.7 (0.1)
  Overall sexual satisfaction 4.1 (0.3) -0.8 (0.4) -0.7 (0.3) 4.7 (0.1) -1.1 (0.2) -0.8 (0.1)

ADT, antidepressant treatment; LOCF, last observation carried forward; MGH-SFI, Massachusetts General Hospital Sexual Functioning Inventory; OC, observed case; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

MGH-SFI item scores range from 1 (greater than normal) to 6 (totally absent). A negative change score signifies improvement.